EMA Veterinary Committee Recommends Approval for New Dog, Pig, and Horse Medicines
The European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) released recommendations from its meeting held between 3 and 5 November 2026. The committee endorsed marketing authorisations for several new animal treatments. These include Scovella (velagliflozin), a treatment for horses facing Equine Metabolic Syndrome. Scovella is the first product recommended under a limited market regulatory framework established by Regulation (EU) 2019/6, which took effect in 2022. The committee also approved positive opinions for dog treatments such as Credelio Quattro for parasites, Laverdia for lymphoma, and Nobivac PLUS DHPPi / Leptos for puppy vaccinations. Pig farmers gained a positive recommendation for Streptoporc to protect piglet health through pregnant sows. For animal owners and livestock managers, these decisions mean new treatments and vaccines may soon reach the market. The committee also extended the authorization of two avian influenza vaccines for one year and added aggression as a very rare side effect for Zenrelia.
What was announced
The Committee for Veterinary Medicinal Products adopted positive opinions for several new veterinary medicines during its November 2026 meeting. For dogs, it recommended Credelio Quattro to treat internal and external parasites, Laverdia to treat certain stages of lymphoma in home settings, and Nobivac PLUS DHPPi / Leptos for routine immunisation starting at six weeks of age. For horses, the committee endorsed Scovella to reduce hyperinsulinaemia and laminitis risks. It also approved Streptoporc, a vaccine given to pregnant sows to protect piglets against Streptococcus suis.
The committee modified existing product approvals as well. Zenrelia will now list aggression as a very rare adverse event. Credelio received approval to add ear mite infestations to its scope. Additionally, the validity of two avian influenza vaccines, Vaxxinact H5 and Vaxxitek HVT+IBD+H5, was extended by one year under exceptional circumstances.
What it means
A positive opinion from the committee is a major regulatory step towards commercial availability in the European Union. Scovella is the first medicine recommended under the limited market regulatory pathway created under rules that took effect in 2022. This pathway relies on customized documentation requirements for medicines aimed at smaller markets.
The updates to existing drugs reflect ongoing safety monitoring and technical studies. Vaccine makers for Bluetongue virus and epizootic haemorrhagic disease met specific test obligations regarding shelf life and potency data. Meanwhile, a joint inter-agency report on antimicrobial resistance (JIACRA V) will publish on 10 December, incorporating environmental data alongside human and animal health statistics.
What the announcement does not tell us
The summary does not state when the European Commission will issue final decisions or when these medicines will become available in pharmacies and veterinary clinics. It does not provide the pricing or exact costs for any of the recommended treatments.
The text also lacks detail regarding the specific clinical trial data, sample sizes, or success rates for the newly endorsed drugs. While Zenrelia added aggression as a very rare side effect, the document does not explain how many animals experienced this reaction during monitoring. Finally, the announcement does not explain why the avian influenza vaccines remain restricted to authorization under exceptional circumstances rather than standard licensing.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is European Medicines Agency News’s own. Always check the original before acting on anything here.
CVMP opinions on veterinary medicinal products Further to the re-examination of the opinion adopted by the Committee during its June 2026 meeting, the Committee adopted a…
Opens www.ema.europa.eu
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.